Incorporated in 2001, Windlas Biotech Ltd is one of the main agencies within the pharmaceutical formulations settlement improvement and production groups (CDMO) phase in India. The business enterprise offers a variety of CDMO services from product discovery to product improvement, licensing, and industrial production of universal products such as complex generics.
It in addition sells its very own branded merchandise inside the exchange generics and OTC markets. Currently, the point of interest of the business enterprise is to launch complex popular merchandise within the continual healing class associated with lifestyle-associated issues. The enterprise operates in 3 verticals; 1. CDMO Products and offerings, 2. Domestic trade generics and Over-the-counter (OTC) market (nutraceutical and fitness supplement products), and 3. Export.
Leading pharma corporations i.E. Pfizer Ltd, Sanofi India Ltd, Cadila Healthcare Ltd, Emcure Pharmaceuticals Ltd, Eris Lifesciences Ltd, Intas Pharmaceuticals Ltd, and Systopic Laboratories Private Limited are a number of the marquee clients of Windlas Biotech. Its manufacturing centers are located at Dehradun with an established working capacity of 7,063.83 million capsules/ tablets, 54.Forty six million pouch/ sachet, and 61.08 million liquid bottles.
Leading marketplace player inside the home pharmaceutical components CDMO phase.
Strong focus on the continual healing class.
Cutting-edge manufacturing facilities in Dehradun, Uttarakhand.
Professional and skilled Promoters and a senior management group.
An progressive product portfolio of complex established products.
Robust economic overall performance song report.
Ashok Kumar Windlass, Hitesh Windlass, Manoj Kumar Windlass, and AKW WBL Family Pvt Trust are the employer promoters.
|Particulars||For the year/period ended (₹ in million)|
|Profit After Tax||96.74||162.13||638.22||111.98|
Objects of the Issue:
- To purchase equipment required for capacity expansion of our existing facility at Dehradun Plant IV.
- To finance incremental working capital requirements of the company.
- Repayment/prepayment of company’s borrowings.
- General corporate purposes.
Windlas Biotech IPO Details
|IPO Opening Date||Aug 4, 2021|
|IPO Closing Date||Aug 6, 2021|
|Issue Type||Book Built Issue IPO|
|Face Value||₹5 per equity share|
|IPO Price||₹448 to ₹460 per equity share|
|Market Lot||30 Shares|
|Min Order Quantity||30 Shares|
|Listing At||BSE, NSE|
|Issue Size||[.] Eq Shares of ₹5|
(aggregating up to ₹401.54 Cr)
|Fresh Issue||[.] Eq Shares of ₹5|
(aggregating up to ₹165.00 Cr)
|Offer for Sale||5,142,067 Eq Shares of ₹5|
(aggregating up to ₹236.54 Cr)
Windlas Biotech IPO Tentative Timetable
The Windlas Biotech IPO open date is Aug 4, 2021, and the close date is Aug 6, 2021. The issue may list on Aug 17, 2021.
|IPO Open Date||Aug 4, 2021|
|IPO Close Date||Aug 6, 2021|
|Basis of Allotment Date||Aug 11, 2021|
|Initiation of Refunds||Aug 12, 2021|
|Credit of Shares to Demat Account||Aug 13, 2021|
|IPO Listing Date||Aug 17, 2021|
Windlas Biotech IPO Lot Size
The Windlas Biotech IPO market lot size is 30 shares. A retail-individual investor can apply for up to 14 lots (420 shares or ₹193,200).
Windlas Biotech IPO Promoter Holding
|Pre Issue Share Holding||78%|
|Post Issue Share Holding||65.16%|
Windlas Biotech IPO Registrar
Link Intime India Private Ltd
Link Intime India Private Ltd
C 101, 247 Park, L.B.S.Marg,
Vikhroli (West), Mumbai – 400083
Phone: +91-22-4918 6270
Email: [email protected]